U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07227168) titled 'A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer' on Nov. 07.
Brief Summary: This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts:
* Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF).
* Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity.
* Part 1C is a dose escalation of STRO-004 combined with pembr...